ProQR Therapeutics

Yahoo Finance • 21 days ago

Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple.Growing Optimism About ProQR Therapeutics N.V. (PRQR)’s RNA Editing Platform and Future Clinical Catalysts As of March 19, 2026... Full story

Yahoo Finance • last month

ProQR Announces Year End 2025 Operating and Financial Results

ProQR Therapeutics N.V. Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026 Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3) Ended 2025 with... Full story

Yahoo Finance • 4 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated A... Full story

Yahoo Finance • 4 months ago

Faron Pharmaceuticals Ltd: Appointment of CFO

TURKU, FI / ACCESS Newswire / December 1, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Jurriaan Dekkers as the company's... Full story

Yahoo Finance • 5 months ago

Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading

(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from Novembe... Full story

Yahoo Finance • 5 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected b... Full story

Yahoo Finance • 6 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA ed... Full story

Yahoo Finance • 6 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated A... Full story

Yahoo Finance • 8 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featu... Full story

Yahoo Finance • 9 months ago

ProQR Therapeutics' SWOT analysis: RNA editing pioneer's stock faces clinical hurdles

ProQR Therapeutics N.V. (NASDAQ:PRQR), a biotechnology company specializing in RNA editing technology, is making significant strides in its clinical development pipeline. The company’s innovative Axiomer platform has garnered attention fro... Full story

Yahoo Finance • 10 months ago

ProQR stock advances as JMP reiterates bullish stance on RNA editing

Investing.com - ProQR Therapeutics N.V. (NASDAQ:PRQR) stock rose Tuesday, extending its impressive 11.92% gain over the past week, after JMP Securities reiterated its Market Outperform rating and $8.00 price target on the RNA editing compa... Full story

Yahoo Finance • 10 months ago

ProQR submits clinical trial application for RNA editing therapy

LEIDEN/CAMBRIDGE - ProQR Therapeutics NV (NASDAQ:PRQR), a $228.59 million market cap biotechnology company that has seen an 11.34% gain in the past week, has submitted a Clinical Trial Application to the European Medicines Agency for its l... Full story

Yahoo Finance • 10 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing Pro... Full story

Yahoo Finance • last year

ProQR Announces Year End 2024 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in... Full story

Yahoo Finance • 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position... Full story

Yahoo Finance • 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strength... Full story

Yahoo Finance • 3 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA ed... Full story

Yahoo Finance • 3 years ago

ProQR Therapeutics Provides Update on Ophthalmic Assets

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previ... Full story

Yahoo Finance • 3 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA edi... Full story

Yahoo Finance • 3 years ago

ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability

We feel now is a pretty good time to analyse ProQR Therapeutics N.V.'s (NASDAQ:PRQR) business as it appears the company may be on the cusp of a considerable accomplishment. ProQR Therapeutics N.V., a biotechnology company, focuses on the d... Full story